Tradestie Institutional Equity Comparison Engine
DXCM vs PHG โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DXCM Overall Edge
DXCM Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DexCom, Inc. (DXCM) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while PHG counters with relative strength in Valuation. Fundamentally, DXCM trades at 25.3x Forward P/E with 24.0% operating margin (+11.2% YoY revenue) versus PHG at 14.0x Forward P/E and 8.8% operating margin (+2.1% YoY). In options structure, DXCM sits in CONSOLIDATION (15th %ile IV; Dealer Gamma Walls on Pro) against PHG sits in SURGE (51st %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
PHG
DXCM 25.3x vs PHG 14.0x Fwd P/E
Growth & Margin Winner
DXCM
Op Margin 24.0% vs 8.8% ยท YoY +11.2% vs +2.1%
Momentum & Technical Winner
DXCM
1Y +32.8% vs +5.7% ยท 52W Pos 63% vs 51%
Options & Structure Winner
DXCM
CONSOLIDATION (15th %ile IV) vs SURGE (51st %ile IV)
DXCM
NASDAQ
DexCom, Inc.
Surgical & Medical Instruments & Apparatus
$79.32
-1.08% 1D
Market Cap
$29.9B
1M Return
+1.28%
1Y Return
+32.8%
Forward P/E
25.3x
Unified AI Score
50.8 / 100
HOLD
Tech 49.0
Fund 56.0
Flow 68.0
Mom 54.0
PHG
NYSE
Koninklijke Philips N.V.
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$28.61
-2.19% 1D
Market Cap
$28.6B
1M Return
+6.28%
1Y Return
+5.73%
Forward P/E
14.0x
Unified AI Score
40.3 / 100
SELL
Tech 15.0
Fund 39.0
Flow 57.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
DXCM +32.8%
PHG +5.73%
Spread: +27.07 pp (DXCM Lead)
Pillar 3 Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)
| Period | DXCM Revenue | PHG Revenue | DXCM Op. Margin | PHG Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| Q3 '25 | $4.84B | $17.2B | 20.1% | 7.7% | DXCM |
| Q4 '25 | $5.04B | $20.4B | 25.6% | 11.1% | DXCM |
| Q1 '26 | $4.77B | $15.6B | 21.4% | 6.2% | DXCM |
| Q2 '26 | $5.23B | $17.4B | 24.3% | 14.0% | DXCM |
| Q3 '26 | $5.38B | $17.6B | 24.3% | 3.8% | DXCM |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | DXCM | PHG | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $29.9B | $28.6B | Larger Scale | DXCM |
| Trailing P/E Ratio Valuation | 31.6x | 25.4x | Lower Multiple | PHG |
| Forward P/E Ratio Valuation | 25.3x | 14.0x | Lower Multiple | PHG |
| Revenue Growth (YoY) Growth | +11.2% | +2.1% | Higher Growth | DXCM |
| Operating Margin (TTM) Profitability | 24.0% | 8.8% | Higher Margin | DXCM |
| Net Profit Margin Profitability | 19.4% | 5.4% | Higher Margin | DXCM |
| Return on Equity (ROE) Capital Efficiency | 37.7% | 8.6% | Higher ROE | DXCM |
| 52-Week Range Position Momentum | 63% ($57โ$93) | 51% ($24โ$33) | Stronger Trend | DXCM |
| Beta / 30D Volatility Risk Regime | 0.59ฮฒ ยท 43% Vol | 0.71ฮฒ ยท 38% Vol | Lower Realized Risk | PHG |
| Unified Institutional Score Composite Signal | 50.8 / 100 (HOLD) | 40.3 / 100 (SELL) | Higher Composite | DXCM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full DXCM vs PHG Buy Guide
DXCM
CONSOLIDATION
73d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
15th %ile
IV Regime
Compressed (<25th %ile)
PHG
SURGE
12d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
51st %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither DXCM nor PHG registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.